RevMed Reports Promising Phase 1/2 Results for Daraxonrasib Plus GnP

Share on Social Media

Revolution Medicines daraxonrasib combined with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer.

Revolution Medicines reports a 60.7% response rate and 12.8-month median PFS with daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.

Written By: Sravani Pamanji, PharmD

Reviewed By: Pharmacally Editorial Team

Revolution Medicines reported updated clinical findings for RASONQUE® (daraxonrasib) combined with gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The results, announced on November 19, 2026, are from the Phase 1/2 RMC-GI-102 study and were scheduled for presentation during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, on November 20.

The updated analysis demonstrated substantial antitumour activity, with a confirmed objective response rate of 60.7% and median progression-free survival of 12.8 months. The findings provide further clinical evidence supporting the evaluation of daraxonrasib alongside chemotherapy in the first-line treatment setting.

RMC-GI-102: Study Design and Patient Population

RMC-GI-102 (NCT06445062) is an open-label Phase 1/2 study evaluating daraxonrasib-based treatment approaches in patients with gastrointestinal solid tumours. One treatment cohort assesses daraxonrasib combined with GnP in previously untreated metastatic PDAC.

As of September 28, 2026, 61 patients in this first-line cohort had received daraxonrasib at a dose of 200 mg alongside GnP, with a median follow-up of 18.3 months. The updated findings build on earlier results presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, incorporating additional patients and longer follow-up.

Updated Clinical Findings: Tumour Response and Survival

The updated analysis demonstrated antitumour activity across multiple efficacy measures:

  • Confirmed objective response rate: 60.7% (95% CI: 47.3–72.9).
  • Complete response rate: 8.2%.
  • Disease control rate: 90.2% (95% CI: 79.8–96.3).
  • Median duration of response: 11.1 months (95% CI: 7.6–18.4).
  • Median progression-free survival: 12.8 months (95% CI: 10.8–18.4).
  • Estimated 12-month overall survival: 76.6% (95% CI: 63.7–85.4).

The findings indicate substantial antitumour activity, with a high proportion of patients achieving tumour response or disease control. The duration of response suggests that treatment activity was maintained among responders, while the progression-free and overall survival estimates provide additional evidence of potential clinical benefit. However, the absence of a randomized comparator prevents conclusions about whether adding daraxonrasib improves outcomes over GnP alone.

Daraxonrasib: Targeting the Active RAS Pathway

Daraxonrasib is an oral, RAS(ON) multi-selective, noncovalent tri-complex inhibitor developed by Revolution Medicines. It is designed to target active, GTP-bound forms of RAS proteins through a cyclophilin A (CypA)-mediated mechanism. Daraxonrasib first binds intracellular CypA, forming a binary complex that subsequently engages active RAS to create an inhibitory tri-complex.

This complex blocks interactions between RAS and downstream effector proteins and promotes GTP hydrolysis, converting active RAS into its inactive GDP-bound state. These actions suppress signalling pathways involved in tumour growth and survival. Daraxonrasib is being investigated as both monotherapy and in combination with established chemotherapy.

Safety and Tolerability

Revolution Medicines reported that the safety profile of daraxonrasib plus GnP was consistent with the previously observed safety profiles of the individual treatments. However, the November 19 announcement did not provide detailed adverse-event frequencies, grade-specific toxicities or treatment discontinuation rates for this updated cohort. Further assessment will depend on the complete clinical presentation and subsequent safety reporting.

Phase 3 Development: RASolute 303

Revolution Medicines is evaluating daraxonrasib in the global Phase 3 RASolute 303 study (NCT07491445), a randomized, open-label, three-arm trial in previously untreated metastatic PDAC.

The study compares daraxonrasib monotherapy and daraxonrasib combined with GnP against GnP alone. Its primary endpoints include progression-free survival and overall survival, allowing investigators to assess whether either daraxonrasib-based approach improves outcomes over standard chemotherapy.

The FDA granted Breakthrough Therapy Designation to RASONQUE combined with GnP in September 2026 for treatment-naïve metastatic pancreatic cancer. The designation was based on preliminary clinical findings in patients with RAS-mutant disease and is intended to facilitate expedited development and review. However, the combination remains investigational in this first-line setting and has not received FDA approval.

Clinical Interpretation

The updated RMC-GI-102 findings strengthen the clinical evidence supporting further evaluation of daraxonrasib in first-line metastatic pancreatic cancer. The combination demonstrated substantial antitumour activity and encouraging survival estimates, supporting its continued development alongside established chemotherapy.

Nevertheless, the small cohort size and absence of a randomized comparator limit conclusions regarding comparative efficacy and survival benefit. RASolute 303 will be important in determining whether the observed treatment activity translates into improved clinical outcomes over gemcitabine and nab-paclitaxel alone. Its findings will help establish the potential role of daraxonrasib-based treatment in the first-line management of metastatic PDAC.

References

Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026, Revolution Medicines.  November 19, 2026.

Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors, ClinicalTrials.gov ID NCT06445062

RASolute 303: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients with Metastatic Pancreatic Adenocarcinoma, ClinicalTrials.gov ID NCT07491445

About the Writer

Sravani Pamanji is a PharmD (LinkedIn) professional with experience in scientific writing, medical literature review, drug profile preparation, and clinical case documentation. She has contributed to scientific publication and presented at the 74th Indian Pharmaceutical Congress. Her training includes ICH GCP E6(R3), scientific research, and medication safety. She is passionate about evidence-based medical communication and accurate dissemination of clinical and pharmaceutical information.


Share on Social Media
Scroll to Top